Neuroendocrine tumors: Role of interventional radiology in therapy

Radiographics

Volumn 28, Issue 4, 2008, Pages 1131-1145

  Steward, Michael J ^a   Warbey, Victoria S ^a   Malhotra, Anmol ^a   Caplin, Martyn E ^a   Buscombe, John R ^a   Yu, Dominic ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL TUMOR; HUMAN; INTERVENTIONAL RADIOLOGY; LIVER TUMOR; METHODOLOGY; NEUROENDOCRINE TUMOR; RADIOGRAPHY; REVIEW;

GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS; RADIOGRAPHY, INTERVENTIONAL;

EID: 53149139919     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.284075170     Document Type: Article

References (43)

1. Socia E, Kloppel G, Sobin LH, et al. Histologic typing of endocrine tumors. In: WHO international histological classifcation of tumors. Heidelberg, Germany: Springer Verlag, 2000.
2. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005;23: 70-78.
3. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90(6): 3392-3400.
4. Musunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 2006;141:1000-1004.
5. Hodul P, Malafa M, Choi J, Kvols L. The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. Cancer Control 2006;13(1):61-71.
6. McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005;237: 718-726.
7. Touzios JG, Kiely JM, Pitt SC, et al. Neuroen-docrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005;241: 776-785.
8. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 1999;10:397-403.
9. Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006;13(1): 72-78.
10. Loewe C, Schindl M, Cejna M, Niederle B, Lam-mer J, Thurnher S. Permanent transarterial embo-ization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003;180:1379-1384.
11. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120(4):302-309.
12. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001;130: 677-685.
13. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994;116: 1111-1117.
14. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293-2301.
15. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroen-docrine tumors: variables affecting response rates and survival. Cancer 2005;104:1590-1602.
16. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumors. Best Pract Res Clin Gastroenterol 2005;19(4):585-594.
17. Roche A, Girish BV, De Baere T, et al. Trans-catheter arterial chemoembolization as frst-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003;13:136-140.
18. Therasse E, Breittmayer F, Roche A, et al. Trans-catheter chemoembolization of progressive car-cinoid liver metastases. Radiology 1993;189: 541-547.
19. Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007;188:1201-1207.
20. Madoff DC, Abdalla EK, Gupta S, et al. Trans-hepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol 2005;16(2 pt 1): 215-225.
21. Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol 2005;16:779-790.
22. Teunissen JJ, Kwekkeboom DJ, de Jong M, Esser JP, Valkema R, Krenning EP. Peptide receptor ra-dionuclide therapy. Best Pract Res Clin Gastroenterol 2005;19(4):595-616.
23. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
24. Krenning EP, Teunissen JJ, Valkema R, deHerder WW, de Jong M, Kwekkeboom DJ. Molecular radiotherapy with somatostatin analogs for (neuro-) endocrine tumors. J Endocrinol Invest 2005;28 (11 suppl):146-150.
25. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors: peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007;21(1):111-129.
26. Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36(2): 147-156.
27. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-155.
28. Belhocine T, Foidart J, Rigo P, et al. Fluorode-oxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun 2002;23:727-734.
29. Groves AM, Win T, Haim SB, Ell PJ. Non-18F-FDG PET in clinical oncology. Lancet Oncol 2007;8:822-830.
30. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcome? J Am Coll Surg 2000;190:432-445.
31. Atwell TD, Charboneau, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 2005;28:409-421.
32. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002;26:985-990.
33. Henn AR, Levine EA, McNulty W, Zagoria RJ. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendo-crine syndromes. AJR Am J Roentgenol 2003;181: 1005-1010.
34. Gillams A, Cassoni A, Conway G, et al. Radio-frequency ablation of neuroendocrine liver metas-tases: the Middlesex experience. Abdom Imaging 2005;30:435-441.
35. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108:1091-1096.
36. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumors. Gut 2005;54(suppl 4):iv1-iv16.
37. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors. Neuroendocrinology 2004; 80:394-424.
38. Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 1995;76: 501-509.
39. Sheen AJ, Poston GJ, Sherlock DJ. Cryotherapeutic ablation of liver tumours. Br J Surg 2002;89: 1396-1401.
40. Tait IS, Yong SM, Cuschieri SA. Laparoscopic in situ ablation of liver cancer with cryotherapy and radiofrequency ablation. Br J Surg 2002;89: 1613-1619.
41. Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 2006;17: 1235-1250.
42. Livraghi T, Vettori C, Lazzaroni S. Liver metastases: results of percutaneous ethanol injection in 14 patients. Radiology 1991;179:709-712.
43. Giovannini M. Percutaneous alcohol ablation for liver metastases. Semin Oncol 2002;29(2): 192-195.